Capricor Investigation Overview
BFA is investigating whether Capricor Therapeutics, Inc. committed securities fraud by making false and misleading statements to investors regarding Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy, and the clinical trial data supporting its regulatory submissions. Investors may be able to file a class action to potentially recover losses.
If you lost money on your Capricor investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is Capricor being investigated for Securities Fraud?
Capricor is being investigated for securities fraud following a significant stock drop. The decline in Capricor’s stock price caused significant losses to investors.
Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an investigational cell therapy being developed for Duchenne muscular dystrophy.
BFA is investigating whether Capricor misled investors about Deramiocel’s clinical data, including the company’s statements concerning positive topline results and its regulatory path with the FDA.
Why did Capricor’s Stock Drop?
On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting concerning Deramiocel. The FDA briefing documents reportedly raised concerns about post-hoc changes to Capricor’s statistical analysis plan, including changes to the methodology for calculating the primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded.
This news caused the price of Capricor stock to decline $12.70 per share, or 64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per share on July 27, 2026, the following trading day.
Capricor Therapeutics ($CAPR) Stock Chart
Image Caption: NASDAQ online chart showing Capricor Therapeutics’ stock drop following the July 27, 2026 disclosure.
How Do I Submit My Information?
If you lost money when Capricor Therapeutics securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
adam@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of the class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
